BACKGROUND: This study was designed to identify preoperative predictors of survival in surgically treated patients with metastatic epidural spinal cord compression (MESCC), to examine how these predictors are related to 8 prognostic models, and to perform the first full external validation of these models in accordance with the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement. METHODS: One hundred forty-two surgically treated patients with MESCC were enrolled in a prospective, multicenter North American cohort study and were followed for 12 months or until death. Cox regression was used. Noncollinear predictors with < 10% missing data, with 10 events per stratum, and with P <.05 in a univariate analysis were tested through a backward stepwise selection. For the original and revised Tokuhashi prognostic scoring systems (PSSs), Tomita PSS, modified Bauer PSS, van der Linden PSS, Bartels model, Oswestry Spinal Risk Index, and Bollen PSS, this study examined calibration graphically, discrimination with Harrell c-statistics, and survival stratified by risk groups with the Kaplan-Meier method and log-rank test. RESULTS: The following were significant in the univariate analysis: type of primary tumor, sex, organ metastasis, body mass index, preoperative radiotherapy to MESCC, physical component (PC) of the 36-Item Short Form Health Survey, version 2 (SF-36v2), and EuroQol 5-Dimension (EQ-5D) Questionnaire. Breast, prostate and thyroid primary tumor (HR: 2.9; P 5.0005), presence of organ metastasis (hazard ratio (HR): 2.0; P 5 .005) and SF-36v2 PC (HR: 0.95; P < .0001) were associated with survival in multivariable analysis. Predicted prognoses poorly matched observed values on calibration plots; Bartels model calibration slope was 0.45. Bollen PSS (0.61; 95% CI: 0.58-0.64) and Bartels model (0.68; 95% CI: 0.65-0.71) had the lowest and highest c-statistics, respectively. CONCLUSIONS: The primary tumor type (breast, prostate, or thyroid), an absence of organ metastasis, and a lower degree of physical disability are preoperative predictors of longer survival for surgical MESCC patients. These results are in keeping with current models. This full external validation of 8 prognostic PSSs or model of survival in surgical MESCC patients has revealed that calibration is poor, especially for long-term survivors, whereas discrimination is possibly helpful.
INTRODUCTION
Of the 5% to 10% of cancer patients who develop spinal metastases, 1, 2 approximately 10% undergo surgical treatment. 3 With the goal of achieving a tangible clinical benefit, surgery is generally offered to patients with metastatic epidural spinal cord compression (MESCC) with a life expectancy of at least 3 months. 4, 5 As a result, surgical MESCC patients likely represent a cohort of patients with a better clinical status than those treated nonsurgically. 6, 7 It is thus critical to evaluate the most important preoperative predictors of survival in this specific subset of patients.
Several prognostic scoring systems (PSSs) or models of survival for MESCC patients are available, but none seem to be used consistently. 8 The original and revised Tokuhashi PSSs, 9 ,10 the New England Spinal Metastasis Score (NESMS), 11 and the Skeletal Oncology Research Group (SORG) nomogram 12 were developed using a cohort of surgical patients. Conversely, the PSSs by van der Linden et al 13 and Rades et al 14 as well as the model by Bartels et al 15 were derived from data from patients who underwent radiation therapy (RT) treatment; the modified Bauer PSS, 6 the Oswestry Spinal Risk Index (OSRI), 16 and the Bollen PSS 17 used a mixed cohort; and Tomita et al 18 did not clarify the type of treatment. Moreover, only the OSRI was developed using prospectively collected data.
A recent systematic review of the literature revealed that the current body of evidence exploring prognostic factors of survival in surgically treated MESCC patients has a moderately high risk of bias due to shortfalls in the design, conduct, analysis, and reporting of studies. Consequently, the strength of the overall body of evidence for predictors of survival in this patient population is low. 19 It is recognized that clinical data gathered prospectively are more complete and precise than those obtained retrospectively 20 and that multivariate analyses provide more accurate predictive estimates than single predictors. 21 Furthermore, external validation is intrinsic to the establishment of prognostic models in clinical practice. 22 Unfortunately, many published reports have highlighted the poor quality of validation studies. [23] [24] [25] The Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement proposes a checklist to reduce the risk of bias when one is developing or validating multivariate diagnostic and prognostic models. 26 We are not aware of any full external validation (ie, an examination by independent investigators of outcome predictions in a different participant sample than the derivation sample) of current MESCC prognostic models conducted in accordance with the TRIPOD statement with prospectively collected data.
Given the number of existing PSSs or models and the limited evidence related to performance, this study aimed at evaluating current models rather than developing a new model. Therefore, with rigorously collected prospective data, our goals were 3-fold:
1. To identify key preoperative clinical factors associated with overall survival in adult patients treated surgically for a single MESCC lesion according to the methodology highlighted by the TRIPOD statement. 2. To examine how these preoperative predictors are related to current PSSs or models of survival developed with retrospective data from MESCC patients who underwent surgery and/or RT. 3. To perform a full external validation fulfilling the TRI-POD checklist and compare the performance of the following PSSs or models: the modified Bauer PSS, the original and revised Tokuhashi PSSs, the Tomita PSS, the van der Linden PSS, the Bartels model, the ORSI, and the Bollen PSS.
Notably, we could not validate 1) the NESMS and the SORG nomogram because the preoperative serum albumin level, hemoglobin level, and white blood cell count were not available or 2) the Rades PSS because one of the predictors is the time to develop motor deficits before RT and not all patients in our cohort developed motor deficits before surgery.
MATERIALS AND METHODS

Design, Participants, Setting, and Data Collection
The AOSpine North American MESCC study is a prospective, multicenter, observational cohort study that involved 142 adult patients who underwent spinal decompressive surgery with or without stabilization or reconstruction for a single symptomatic MESCC lesion. Patients underwent surgery at 1 of the 10 participating centers from March 1, 2008 (the start of recruitment), to April 30, 2012 (the end of recruitment), for 1 of the 3 following indications: intractable pain, neurologic deficits, or imminent/overt spinal instability (Fig. 1) . Notably, radioresistant tumors were one of the exclusion criteria listed in the AOSpine North America MESCC study protocol. The advent of stereotactic body radiation therapy is changing the paradigm of tumor radioresistance with a high rate of local control across histologies. This includes histologies traditionally viewed as radioresistant, such as renal cell carcinoma and sarcoma. 27 Therefore, no patients were excluded on the premise of having a radioresistant tumor. Decisions related to the surgical procedure and postoperative RT were at the discretion of the treating team. The accuracy of the data collection and the adherence to the study protocol were externally monitored (Data Management Center, Seattle, Washington). The research ethics boards of each participating hospital
Cancer September 1, 2018 approved the study protocol. Further details related to the AOSpine North America MESCC study were previously published. 28 The sample size was determined by the available data set.
Outcome and Preoperative Clinical Factors
The outcome of interest was survival (days) after the date of surgery. Patients were followed for at least 12 months postoperatively or until death (from any cause); the last contact was the censor date. Death or last contact was determined by clinic visit, phone call, hospital record, or death registry. Follow-up ended April 15, 2013. Patient characteristics were obtained preoperatively by a qualified member of the surgical or research team during the time between the acquisition of informed consent and surgery. On the basis of the literature, 8, 19, 29, 30 we decided to examine the influence of the following preoperative factors on survival:
1. Categorical variables: sex, site of primary tumor, surgical removal with curative intent of the primary tumor, medical comorbidities, presence and location of extraspinal metastasis, presence of neurologically related bladder and bowel dysfunction, spinal location and number of contiguous vertebral bodies involved by the MESCC lesion, ability to walk 4 steps independently with or without a walking aid, American Spinal Injury Association (ASIA) Impairment Scale (AIS), systemic treatment in terms of chemotherapy and Notably, the time interval was 0 days if the onset of motor impairment preceded or occurred at the same time as the diagnosis of MESCC. No actions were taken to blind the assessment of either the predictive factors of survival or outcome of interest.
Selection of Preoperative Prognostic Factors and Analysis
Missing data were assumed to be missing at random; predictors with > 10% missing data were not considered for analysis. Predictors with < 10 events in a stratum were combined with another stratum as long as the clinical relevance of the predictor was maintained; predictors with-< 10 events in a stratum were not considered for analysis. Strata of nonbinary categorical variables that were not significantly different in the univariate analysis were also combined (Supporting Table 1 ). Collinearity and correlation among all candidate predictors were assessed. In case of collinearity (tolerance < 0.2) or an important correlation (r > 0.5), the most clinically relevant and easily measurable/collectable factor was retained. Selected predictors with a P value < .05 in the univariate analysis were considered in the multivariate analysis. The proportional hazards assumption was tested by the creation of a timedependent variable for each selected predictor, and significant time-dependent terms were added to the final multivariate analysis. The multivariate analysis was conducted with a backward stepwise selection process to determine preoperative clinical factors independently associated with survival.
PSSs or Model
Unfortunately, the Karnofsky performance status (KPS) was not prospectively collected. Although it was not used as a potential predictor of survival in our analysis, it was retrospectively determined because it is a predictor in 6 of the 8 PSSs or model in this external validation. For each patient, 3 clinicians (A.N., 1 neurosurgeon, and 1 orthopedic surgeon) independently assigned a KPS score 31 based on demographic, clinician-assessed, and patientreported data (Supporting Table 2 ) collected at the time of the patient's enrollment. The 3 evaluators were blinded to the predictors and outcome. Any discrepancies between the 3 reviewers were resolved by consensus agreement.
Our data were not fully compatible to fit all PSSs as they were originally published. The PSS by Bollen et al 17 includes the clinical profile predictor, which classifies the different sites of the primary tumor as favorable, moderate, or unfavorable. Although the clinical profile associated with vulvar cancer was not specified, the clinical profile for cervical cancer was unfavorable. Thus, the clinical profile for the patient with vulvar cancer was classified as unfavorable. Our database did not distinguish whether a gastrointestinal (GI) primary cancer originated from the esophagus, stomach, or rectum or whether an organ metastasis was treatable or untreatable. Therefore, sensitivity analyses were conducted to control for these differences. The original Tokuhashi PSS allocates 0 and 2 points to stomach and rectum primary cancers, respectively, whereas the revised Tokuhashi PSS allocates 0 and 4 points, respectively. Therefore, for the original Tokuhashi PSS, in our first analysis, all GI primary cancers were allocated 0 points (original Tokuhashi I), and in the second analysis, all GI primary cancers were allocated 2 points (original Tokuhashi II). Similarly, for the revised Tokuhashi PSS, in our first analysis, all GI primary cancers were allocated 0 points (revised Tokuhashi I), and in the second analysis, all GI primary cancers were allocated 4 points (revised Tokuhashi II). The Tomita PSS categorizes a visceral metastasis as treatable (2 points) or untreatable (4 points). Thus, in our first analysis, metastases to other organs were allocated 2 points (Tomita I), and in our second analysis, they were allocated 4 points (Tomita II).
The Bauer PSS 32 was elaborated to predict survival in cancer patients with skeletal metastases, including metastases to the spinal column and extremities. Bauer et al 32 reported that the "impact of pathologic fracture was evident in the extremity group only." 32 Subsequently, Leithner et al 33 proposed modifying the Bauer PSS for MESCC patients by retaining the 4 other predictors and omitting the "absence of pathologic fracture." Wibmer et al 6 assessed the modified Bauer PSS in their data set consisting of 254 MESCC patients and assigned an overall median survival for each risk group. In this analysis, we used the modified Bauer PSS and the survival predictions as published by Wibmer et al. Table 1 presents the characteristics of the validation data as well as the development data used to generate the 8 PSSs evaluated, and Supporting Table 3 presents the different PSSs and predicted survival.
Statistical Analyses
Means, standard deviations, medians, and ranges were used to describe continuous variables and proportions for categorical variables. Cox regression was used to evaluate the effect of preoperative clinical factors on survival. The Kaplan-Meier method and log-rank tests were used to assess statistical significance between categorical variables. Because Cox regression is a time-to-event analysis, the total number of events (ie, deaths) represents the limiting sample (m). To minimize overfitting, several authors have recommended that a maximum of m/10 predictor degrees of freedom should be included in the multivariate regression analysis. 34, 35 The interrater reliability was assessed with the Fleiss multirater j for determining a patient's KPS. Assessing the performance of PSSs for which the regression model is not available is challenging because predicted probabilities cannot be calculated. Therefore, for all PSSs, we showed the calibration graphically by plotting the predicted proportion of each prognostic group against the observed proportion. In addition, survival was stratified by risk groups and evaluated using the Kaplan-Meier method and log-rank test. For the Bartels model, the calibration slope was estimated via the fitting of a Cox regression model to the survival outcomes in the validation cohort with the prognostic index, that is, the linear component of the Cox model (Xb model ), whose regression coefficients are estimated from the derivation data set as the unique predictor. 36 In addition, the actual and mean predicted survival was plotted against the postoperative follow-up time. Discrimination was examined with the Harrell cstatistic. A P value < .05 was considered significant. Analyses were performed with SAS (SAS/STAT User's Guide, version 9.4; SAS Institute, Cary, North Carolina) and Microsoft Excel 2010.
RESULTS
Descriptive Data
On average, the study enrollment preceded MESCC surgery by 1.4 6 2.98 days (range, 0-21 days). The mean age at surgery was 59 6 12.0 years, and 58.4% of the patients (n 5 83) were male. The most common sites for the primary tumor were the lung (23.9%, n 5 34), kidney (15.5%, n 5 22), breast (14.8%, n 5 21), and prostate (13.4%, n 5 19). The majority of patients (76.1%, n 5 108) suffered from at least 1 comorbidity. Most MESCCs were located in the thoracic spine (81.7%, Table 3 ). The indications for surgical treatment were a neurologic deficit (40.1%, n 5 57), intractable pain (38.7%, n 5 55), and overt/imminent spinal instability (21.1%, n 5 30). All patients underwent open surgery: 10 (7.0%) had an anterior approach, 83 (58.5%) had a posterior approach, and 49 (34.5%) had a combined anterior and posterior approach. Details related to the surgical treatments were provided in a previous publication. 28 A total of 37 patients (26.1%) received preoperative RT. Although postoperative RT was considered for all patients, it was given to 76 patients (53.5%).
Follow-Up and Survival
Overall, the median survival was 230.5 days or slightly more than 7.5 months (3-1085 days; n 5 142). A total of 88 patients died, and 54 were censored. Because a total of 114 patients were followed until death or for at least 365 days after surgery, (ie, the a priori determined study follow-up period; Fig. 1 ), the follow-up rate was 80.3%. Among the 88 patients who died, 8 (9.1%), 40 (45.5%), 56 (63.6%), and 81 (92.1%) died within 30 days, 3 months, 6 months, and 12 months after surgery, respectively.
Prognostic Factors of Survival
Two continuous preoperative candidate predictors were discarded because they had >10% missing data: the time intervals between the diagnosis of primary cancer and MESCC and between the diagnosis of MESCC and the onset of motor impairment (Table 2) . Three nonbinary categorical variables had strata that could be appropriately combined to obtain a stratum with at least 10 events: spinal location, number of contiguous vertebral bodies involved by the MESCC lesion, and AIS grade (Supporting Table 1 ).
On the basis of the literature, 19 ,30 the sites of the primary tumor were classified as the type of primary tumor: I (breast, prostate, or thyroid), II (ovarian, uterine, kidney, skin, bladder, cervical, vulvar, or other), and III (lung, liver, unknown, or GI). In the univariate analysis, although the overall differences between the estimated survival curves for primary tumor types I and II (log-rank P 5 .0430) and types I and III (log-rank P 5 .0007) were significant, the difference was not significant between types II and III (log-rank P 5 .2778). Type II and III primary tumors were thus combined. Despite attempting stratum collapse when appropriate, we discarded 14 categorical predictors because they had fewer than 10 events per stratum (Table 2) . A univariate analysis was conducted for a total of 18 candidate predictors of survival (bolded predictors in Tables 2 and 3) . Eight of these candidate predictors yielded a P value < .05 in the univariate analysis: primary tumor type; sex; organ metastasis; body mass index; preoperative RT to MESCC; and SF-36v2 PC, EQ-5D, and ODI scores (bolded predictors in Table 4 ). Although these 8 predictors were not collinear (tolerance < 0.2), ODI was moderately (r 5 -0.60, P < .0001) and highly (r 5 -0.75, P < .0001) correlated with SF-36v2 PC and EQ-5D, respectively; however, SF-36v2 PC and EQ-5D were only slightly correlated (r 5 0.43, P < .0001). Moreover, ODI was developed as a clinical tool targeting the assessment of low back pain. 37 Therefore, ODI was discarded. Because the proportional hazards assumption was met, the 7 remaining predictors, each with 1 predictor degree of freedom, were assessed with a multivariate Cox regression through a backward elimination process.
Three preoperative clinical factors were significant in the Cox multivariate analysis: the SF-36v2 PC score (hazard ratio [HR], 0.946; 95% confidence interval [CI], 0.921-0.971; P < .0001), the presence of organ metastasis (HR, 1.986; 95% CI, 1.229-3.211; P 5 .0051), and primary tumor type II/III (HR, 2.897; 95% CI, 1.593-5.267; P 5 .0005; Table 5 ). Therefore, at any given time, Abbreviations: AIS, American Spinal Injury Association Impairment Scale; C, cervical; CT, cervicothoracic; MESCC, metastatic epidural spinal cord compression; T, thoracic. Bolded variables were considered for statistical analysis because they had <10% missing data and at least 10 events per stratum. Abbreviations: AIS, American Spinal Injury Association Impairment Scale; C, cervical; CI, confidence interval; CT, cervicothoracic; EQ-5D, EuroQol 5-Dimension Questionnaire; HR, hazard ratio; MESCC, metastatic epidural spinal cord compression; ODI, Oswestry Disability Index; SF-36v2, 36-Item Short Form Health Survey, version 2. Bolded variables were included in the multivariate Cox regression analysis. The variables in italics are the reference groups.
1) for every 1-point increase in the preoperative SF-36v2 PC score, the hazard of dying decreases by an estimated 5.5%; 2) approximately twice as many patients who are known to have organ metastases preoperatively die proportionally to patients with no known organ metastases; and 3) nearly 3 times as many patients with a primary tumor other than a breast, prostate, or thyroid tumor die proportionally to patients with a breast, prostate, or thyroid tumor.
External Validation of Current PSSs or Model
KPS was retrospectively determined (Supporting Table 2 ). The overall interrater j value was 0.70, which represented a substantial degree of agreement. Bartels et al 15 specified the parameter estimates and a link to a Web calculator that provides expected predictions. In contrast, Tokuhashi et al, 9, 10 Tomita et al, 18 van der Linden et al, 13 Leithner et al 33 and Wibmer et al 6 (modified Bauer PSS), Balain et al (OSRI), 16 and Bollen et al 17 proposed PSSs in which a set of variable predictors are assigned a number of points and patients are categorized into different survival groups based on the summation of these points. Among the 129 patients who had complete data for all 8 PSSs or model, 104 died or were followed for at least 1 year after surgery. Figure 2 presents the predicted proportion of each prognostic group against the observed proportion for the 7 PSSs as well as the actual and mean predicted survival curves for the Bartels model. The calibration slope for the Bartels model was 0.45. Figure 3 illustrates survival stratified by risk groups for the 7 PSSs. The difference between all groups was only significant for the van der Linden PSS. 
DISCUSSION
The AOSpine North America MESCC study fulfilled all 5 criteria of a good-quality cohort study: 1) it had a prospective design, 2) the patients were followed for a sufficient period of time for the outcomes of interest to occur, 3) the follow-up rate was 80%, 4) the patients were at a similar point in the course of their disease, and 5) the study accounted for other prognostic factors. 38 Moreover, it was externally monitored (Data Management Center, Seattle, Washington), and this ensured noninformative censoring. In addition, this prognostic study meets the standards of a relatively unbiased study with respect to the 6 bias domains: 1) study participation, 2) study attrition, 3) prognostic factor measurement, 4) outcome measurement, 5) study confounding, and 6) statistical analysis and reporting. 39 Consequently, this study can be considered a high-quality prognostic study with a low risk of bias. Using these rigorously collected prospective data, we identified 3 preoperative factors independently associated with longer overall survival for patients who underwent surgical treatment for a single MESCC lesion: 1) breast, prostate, or thyroid primary tumors; 2) an absence of organ metastasis; and 3) a higher score on the SF-36v2 PC questionnaire.
These prognostic factors are in keeping with current PSSs, including the NESMS and the SORG nomogram. The type of primary tumor is common to all 8 PSSs examined, whereas internal organ/brain metastasis is part of all scoring systems except the OSRI. We used the SF-36v2 PC, which is a patient-reported instrument, whereas the original and revised Tokuhashi PSSs, van der Linden PSS, and OSRI use the KPS score, which is a clinician-assessed parameter. Both the SF-36v2 PC and the KPS provide insight into the general performance status of the patient.
This full external validation of 8 PSSs or model was conducted in accordance with the TRIPOD statement (Supporting Table 4 ). Predictive performance was assessed in terms of calibration and discrimination. Calibration describes the agreement between predicted and observed values. Calibration is harder to evaluate and requires more information related to the original data set used to develop the model. 40 In a calibration plot ( Fig. 2A-G) , where the observed values are plotted against the predicted probabilities, a 45 8 line represents perfect calibration (dotted line in Fig. 2A-G) . Because the derived data sets or full models were not available, calibration in the large could not be performed. Nonetheless, for the original and revised Tokuhashi I and II PSSs, Tomita I and II PSSs, van der Linden PSS, modified Bauer PSS, Bollen PSS and OSRI PSS, plotting the predicted proportion of each prognostic group against the observed proportion showed overall poor calibration. All 7 PSSs tended to predict short-term survival better than longterm survival. In our cohort, there was no patient in the long-term survivor groups for the OSRI, van der Linden PSS, Bollen PSS, or modified Bauer PSS. Except for the OSRI, most PSSs tended to overestimate survival (Fig. 2 ). There were no differences between sensitivity analyses for the original and revised Tokuhashi PSSs as well as the Tomita PSS. The actual and mean predicted survival curves of the Bartels model do not overlap and the calibration slope was well below 1. A slope close to 1 indicates a well-calibrated model, whereas a slope inferior to 1 suggests overfitting of the model to the original derivation data set, where low-risk patients might have predictions that are too low and high-risk patients have predictions that might be high. 41 In this study, the Bartels model underestimated survival (Fig. 2H) . The van der Linden PSS consists essentially of the 3 predictors of survival identified in this study, and it was the only PSS with a significant difference in survival among its 3 risk groups (Fig. 3G) .
Discrimination refers to the ability of a model to differentiate between patients who do and do not experience an event during the study period or to accurately rank patients from low to high risk, with 0.5 indicating that the model is no better than chance and with 1.0 indicating perfect discrimination. None of the PSSs or model demonstrated clearly useful discrimination (c-statistic > 0.75). 42 These results are similar to those of another external validation study 43 that reported c-statistics of 0.64, 0.64, 0.66, and 0.69 for the revised Tokuhashi, Tomita, van der Linden, and Bollen PSSs (external data), respectively. Notably, in our study, the discrimination of the revised Tokuhashi PSS was almost identical to that of the original Tokuhashi PSS. Thus, changing the number of points allocated to the different types of primary tumors did not seem to have improved the discriminative ability of the original PSS.
Although the Bollen and Bartels PSSs had the poorest (0.61) and best discrimination (0.68) in this study, respectively, they were both essentially developed with a cohort of patients who received RT only. However, it is important for the patient sample to be representative of the intended population. The most recent external validation by Bartels et al 44 supports this fact. They used the data from 58 patients who were treated with surgery followed by RT and from 52 patients who received RT only. They reported that both the overall performance (R 2 D , 0.02 vs 0.35) and the discrimination (c-statistic, 0.55 vs 0.75; D-statistic, 0.32 vs 1.5) were poorer for the surgical group versus the RT group. The fact that patients from the surgical group seemed fundamentally different from those in the RT group was further illustrated graphically: the estimated survival curve and the actual survival curve were very close for the radiation group, whereas they were quite far apart for the surgical group. In fact, similarly to our results, the Bartels model tended to underestimate survival in the surgical group.
Unfortunately, we could not validate the NESMS and the SORG nomogram, which were developed in surgical MESCC patients. Goodwin et al 45 externally validated the NESMS and reported adequate discrimination (0.73). Pereira et al 46 conducted an external validation of their own model and concluded that the SORG nomogram accurately predicted 3-and 12-month survival (0.74 and 0.78, respectively). The SORG nomogram was best at predicting 3-month survival in comparison with the revised Tokuhashi PSS (0.71) and at predicting 12-month survival in comparison with the revised Tokuhashi PSS, Tomita PSS, modified Bauer PSS, and NESMS (0.67, 0.72, 0.68 and 0.71, respectively).
This study has several limitations. Because of the relatively small sample size, this study may be underpowered. Although we believe that this cohort is representative of today's surgical MESCC population, it was quite specific. The study included adult patients who underwent surgical treatment for a single cervical or thoracic MESCC lesion (excluding multiple myeloma/plasmocytoma, lymphoma, leukemia, germ cell tumors, and primary cancers of the central nervous system or spine) associated with overt/imminent spinal instability, focal or radicular pain, or neurologic deficits. This specificity may limit the generalizability of our results. No actions were taken to blind the assessment of the predictive factors or the outcome to be predicted. However, because neither the predictors nor the outcome required a subjective judgment of assessment, it is unlikely that this had a significant impact on our results. As reported in the TRIPOD statement, 26 "sample size requirements for validation studies are not well understood, and there is a dearth of empirical evidence to guide investigators." In addition, the KPS was retrospectively obtained, and postoperative treatment would have potentially influenced survival; this could have introduced bias into our evaluation of current PSSs. Finally, other potential predictors of survival, such as primary tumor biomarkers, were not collected. This represents an opportunity for future study and could improve predictive modeling, particularly for those patients with a more favorable prognosis.
In conclusion, life expectancy is an important determinant in the decision-making process for patients with MESCC. However, none of the current PSSs or models are consistently used. With the publication of the TRI-POD statement, the quality of the development and validation of prognostic studies is expected to rise. This study addressed 3 knowledge gaps. Using data from a highquality prognostic study, we identified 3 independent preoperative clinical factors associated with longer overall survival for patients who underwent spinal decompression with or without reconstruction or stabilization for a single MESCC lesion: 1) a breast, prostate, or thyroid primary tumor, 2) an absence of organ metastasis, and 3) a lower degree of physical disability as reflected by a higher score on the SF-36v2 PC questionnaire. These 3 predictors are common to most current scoring systems. Therefore, there seems to be a consensus that these factors should be viewed as key factors of survival and should thus be taken into account during the informed discussion between physicians and their patients regarding therapeutic planning. Finally, we performed the first full external validation of 8 current PSSs or model in accordance with the TRIPOD statement, which revealed that calibration was poor overall and that discrimination was possibly helpful. Therefore, although these PSSs or model tend to be informative for short-term survivors, clinicians should use them with caution, especially if they are applied in a population different from the development population. The SORG nomogram seems to be a promising prognostic tool for surgically treated MESCC patients. However, a full external validation using an independent, prospectively collected data set and performed by a different group of investigators in accordance with the TRIPOD guideline would be recommended for further establishing such prognostic tools in clinical practice. 
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